Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Spirocyclic POM Analogues Target MmpL3 in TB
2026-09-21
This 2024 Bioorganic Chemistry study develops spirocyclic phenyl oxazole methyl analogues as a new anti-tubercular chemotype and identifies MmpL3 as the likely target of the lead compound 5c. The lead showed potent activity against drug-susceptible and resistant Mycobacterium tuberculosis isolates, with supporting evidence from spontaneous mutant generation, computational docking, ADME, pharmacokinetic, and cytotoxicity studies.
-
Deracoxib and Piroxicam in Canine Osteosarcoma
2026-09-21
This in vitro study compared deracoxib and piroxicam across canine osteosarcoma cell lines and examined whether reduced viability was associated with apoptosis. Deracoxib showed broader and greater cytotoxic activity than piroxicam, but the effective concentrations exceeded typical plasma exposure, emphasizing the gap between cell-culture activity and clinical translation.
-
Making Cellular ROS Data Translational
2026-09-20
A mechanistic and strategic guide to using DCFH-DA-based live-cell ROS measurement to connect oxidative stress biology with translational decision-making, informed by recent findings in PM2.5-induced COPD research.
-
Gamithromycin: PK/PD Workflows for Respiratory Models
2026-09-19
Build more predictive respiratory infection assays with Gamithromycin (ML-1709460) by pairing matrix-matched MIC testing with AUC24/MIC analysis. This workflow connects bench antimicrobial measurements with lung exposure, animal PK/PD, and pathogen-specific treatment questions.
-
2X Taq PCR Master Mix for CRC Research
2026-09-19
Use 2X Taq PCR Master Mix for streamlined endpoint PCR in colorectal cancer genotyping, construct screening, and sequence-validation workflows. Its integrated loading dye and Taq-generated adenine overhangs simplify gel analysis and TA cloning while preserving a clear boundary around applications that require proofreading or quantitative amplification.
-
Cassava A20/AN1 Genes and Abiotic Stress Tolerance
2026-09-18
The reference study functionally distinguishes cassava Metip4, Metip8, and Metip11 across drought, salinity, temperature, and metal stresses using complementary genetic, cellular, physiological, and transcriptomic approaches. Its main contribution is evidence for functional convergence across several stress conditions alongside gene-specific differences in cadmium and copper responses, providing a framework for prioritizing stress-tolerance genes in cassava.
-
QX77 Workflow for Autophagy and Viability Assays
2026-09-17
This scenario-driven guide explains how QX77, SKU BA3596, can support chaperone-mediated autophagy research, lysosomal receptor regulation, and stem cell experiments while protecting viability and cytotoxicity readouts from common interpretation errors. It separates documented product properties from practical, testable workflow recommendations.
-
UHRF1, Super-Enhancers, and Osteogenesis in SOP
2026-09-17
The reference study identifies a mechanistic connection between UHRF1-dependent 5-methylcytosine remodeling, super-enhancer redistribution, and TGM2-regulated autophagic flux in senile osteoporosis. Its integrated multi-omics and functional experiments suggest that altered epigenetic control of mesenchymal stem cells is a tractable explanation for impaired osteogenesis and bone loss.
-
AAL-993 and the Next Logic of Tumor Angiogenesis
2026-09-16
A mechanistic and translational framework for using AAL-993 as a selective VEGF receptor inhibitor in tumor angiogenesis research, while connecting receptor-level pharmacology with SRC/PI3K/AKT hypotheses and disciplined preclinical validation.
-
Sodium Phosphate Dibasic in Assay Interpretation
2026-09-16
Sodium phosphate dibasic is more than a routine buffer salt: its concentration, matrix effects, and preparation can influence assay interpretation. This article develops a buffer-aware framework linking Na2HPO4 chemistry with biochemical workflows and aquatic toxicity study design.
-
Biotin-16-UTP: Practical RNA Labeling Guide
2026-09-15
Biotin-16-UTP provides a biotin-labeled uridine triphosphate for incorporating affinity handles into RNA during in vitro transcription, supporting RNA detection and purification as well as interaction assays. It is intended for research workflows only; the dossier does not establish a universal substitution ratio, polymerase compatibility profile, diagnostic use, or clinical application.
-
Testosterone Bounce in Degarelix-Treated Prostate Cancer
2026-09-15
This retrospective study identifies a testosterone bounce, defined using a 20 ng/dL nadir and maximum threshold, as a prognostic marker in prostate cancer treated with degarelix. The association with overall and cancer-specific survival, but not progression-free survival, suggests that serial testosterone kinetics may add information beyond a single castration-level measurement.
-
Pioglitazone: From PPARγ Binding to Causal Assays
2026-09-14
Pioglitazone is a selective PPARγ agonist that connects receptor activation with macrophage-state transitions, barrier restoration, and metabolic phenotypes. This article presents a causal assay framework grounded in DSS-induced intestinal inflammation research rather than another routine compound-handling guide.
-
Mavorixafor Hydrochloride: CXCR4 Antagonist Guide
2026-09-14
Mavorixafor hydrochloride, also called AMD-070 hydrochloride, is an oral CXCR4 antagonist that inhibits CXCR4/CXCL12 signaling. Evidence supports its use in WHIM syndrome research and clinical development, while antiviral and Waldenström macroglobulinemia applications remain context-dependent or investigational.
-
Drug Response Metrics in Cancer Cell Models
2026-09-13
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measures capture overlapping but nonidentical dimensions of anticancer drug response. Its central practical implication is that proliferation arrest and cell killing should be measured and interpreted separately, with attention to their relative magnitude and timing.